fluoroquinacrine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	188945
MeSH ID	M0106629

Synonyms (8)

Synonym
fluoroquinacrine
4-n-(6-chloro-2-fluoroacridin-9-yl)-1-n,1-n-diethylpentane-1,4-diamine
1,4-pentanediamine, n4-(6-chloro-2-fluoro-9-acridinyl)-n1,n1-diethyl-
316-83-6
3-fluoro-7-chloro-9-(diethylamino-1-methylbutylamino)acridine
n'-(6-chloro-2-fluoroacridin-9-yl-n,n-diethylpentane-1,4-diamine
4-[(6-chloro-2-fluoroacridin-9(10h)-ylidene)amino]-n,n-diethylpentan-1-amine
DTXSID60953563

Research Excerpts

Compound-Compound Interactions

Excerpt	Reference	Relevance
"To evaluate the antitumor efficacy against metastatic breast cancer of fluoropyrimidines alone and combined with other chemotherapeutic agents, we developed a murine model of breast cancer metastatic to the lung by orthotopically implanting MDA-MB-435S breast tumors into mice."	( [Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung]. Fujioka, A; Fukushima, M; Nakagawa, F; Nukatsuka, M; Ohshimo, H, 2002)	0.31

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (20.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (60.00)	29.6817
2010's	1 (20.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.30 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.09 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.30)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (20.00%)	6.00%
Case Studies	1 (20.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	3 (60.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
uracil 2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder	2.01	1	pyrimidine nucleobase; pyrimidone	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; prodrug; Saccharomyces cerevisiae metabolite
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.02	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
tegafur [no description available]	2.01	1	organohalogen compound; pyrimidines
floxuridine Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.	2.01	1	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; radiosensitizing agent
deoxycytidine [no description available]	3.14	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
doxifluridine doxifluridine : A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.	2.01	1	organofluorine compound; pyrimidine 5'-deoxyribonucleoside	antimetabolite; antineoplastic agent; prodrug
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	3.14	1	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
uftoral UFT(R) drug: a drug containing tegafur and uracil; a biochemical modulator of 5-fluorouracil; used for postoperative chemotherapy of colon cancer; reported to cause severe liver injury; do not confuse with 1-UFT protocol	2.01	1
taxane taxane: produced by Taxomyces andreanae	2.01	1	diterpene; terpenoid fundamental parent

Condition	Relationship Strength	Studies
Infections, Legionella pneumophila [description not available]	2.17	1
Germinoblastoma [description not available]	2.17	1
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	2.17	1
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	2.17	1
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	2.17	1
Pneumonia Infection of the lung often accompanied by inflammation.	2.17	1
Bacteremia The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.	2.17	1
Cancer of Rectum [description not available]	2.02	1
Rectal Neoplasms Tumors or cancer of the RECTUM.	2.02	1
Cancer of Pancreas [description not available]	2.96	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.96	1
Breast Cancer [description not available]	2.01	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.01	1
Cancer of Lung [description not available]	2.01	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.01	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.01	1

chemdatabank.com